MAR 01, 2020 9:01 AM PST

Treating Huntington's Disease With a Gene Therapy That Targets Brain Cells

WRITTEN BY: Carmen Leitch

Huntington's disease (HD) is a rare degenerative brain disorder that is caused by mutations in the Huntington gene (Htt), and neurodegeneration in a part of the brain called the striatum. The most common type appears in a patient's thirties or forties, symptoms include emotional problems, cognitive dysfunction, and uncontrolled twitching or jerking, called chorea. These movements get worse as the disease progresses. People with Huntington's disease might eventually have difficulty swallowing or walking, and their ability to think and reason declines. They live around twenty years after the onset of symptoms.

This is a a newly converted neuron (red) surrounded by astrocytes (green). / Credit: Gong Chen and Zheng Wu

Researchers may have now found a way to treat the disorder by stimulating the growth of new neurons. The work, led by Dr. Gong Chen of Jinan University in China, formerly a professor at Penn State University, has been published in Nature Communications.

"We are developing a series of NeuroD1-based gene therapies to reprogram brain internal glial cells directly into functional new neurons to treat a variety of brain disorders including Huntington's Disease, Alzheimer's disease, stroke, ALS, and many more," said Dr. Chen. "Because every single neuron in our brain is surrounded by supporting glial cells, such direct glia-to-neuron conversion technology offers great advantages over stem cell transplantation therapy in terms of high efficiency of neuroregeneration and no worries about immunorejection," Dr. Chen added.

NeuroD1 is a transcription factor, meaning it helps control the activity of other genes. Previous work by Chen's team has shown that when NeuroD1 is expressed in the mouse brain, a type of brain cell called a cortical astrocyte will convert into a functioning neuron. The researchers then demonstrated that the findings hold true in non-human primate brains.

The neurons that are created using NeuroD1 as a trigger tend to be a kind of cell called a glutaminergic neuron. Around 80 percent of the brain is made of this type of neuron, and they are the primary source of brain activity. Huntington's disease, however, is caused by the degeneration of a type of cell called a GABAergic neuron; these inhibitory neurons are responsible for about 90 percent of the activity in the striatum. The scientists found a way to stimulate the creation of these neurons.

"In order to generate GABAergic neurons, we combined NeuroD1 together with another transcription factor Dlx2, which is known to generate GABAergic neurons during early brain development, and successfully converted striatal astrocytes into GABAergic neurons in HD mice," said the first author of the study Dr. Zheng Wu. "Importantly, here we used the adeno-associated virus (AAV) vectors, which have been approved by FDA as a common gene therapy vector in many clinical trials, to develop a novel gene therapy for the treatment of HD."

Striatal astrocytes were converted directly into GABAergic neurons in about 80 percent of AAV-infected cells, and the astrocytes that remained were able to proliferate so their levels would return to normal. The newly-made neurons were functional and formed connections with other neurons as well as pushing their axons into the correct places.

"The most exciting findings of this HD study are the significant motor functional recovery and remarkable extension of life span among the gene therapy-treated HD mice," Chen noted.

"Our regenerative gene therapy approach is different from conventional gene therapy that typically aims at the mutant genes by either correcting the gene mutations or reducing the mutant gene product, such as reducing mHtt aggregates in HD patients," added Chen. "Obviously, reducing mHtt aggregates at early stage might slow down the disease progression but it cannot regenerate new neurons for the late-stage patients. An ideal approach may be to combine our neuroregenerative approach together with gene correction technology to generate healthy new neurons in future studies."

Sources: AAAS/Eurekalert! via Guangdong-Hongkong-Macau Institute of CNS Regeneration - Jinan University, Nature Communications

About the Author
  • Experienced research scientist and technical expert with authorships on 28 peer-reviewed publications, traveler to over 60 countries, published photographer and internationally-exhibited painter, volunteer trained in disaster-response, CPR and DV counseling.
You May Also Like
MAR 22, 2020
MAR 22, 2020
What is "Shotgun ion mobility mass spectrometry sequencing"?
Research published recently in Nature Communications highlights a new method of mapping an essential family of polysacch ...
MAR 23, 2020
Cell & Molecular Biology
MAR 23, 2020
How a Father's Diet Can Impact the Health of His Offspring
When fathers consume a diet high in fat or low in protein it can increase the risk of metabolic disorders like diabetes ...
MAR 28, 2020
MAR 28, 2020
The Not So Minor Genetic Players in Head and Neck Cancers
Head and neck squamous cell carcinomas (HNSCC) are among the most prevalent cancers among smokers, linked to alcohol con ...
APR 13, 2020
APR 13, 2020
Even Bacteria Align With the Daily Cycle of Day and Night
The majority of living organisms on Earth have adapted in some way to the daily cycle of night and day.
APR 15, 2020
APR 15, 2020
Why More Men than Women Die from COVID-19
As of April 9th, over 60% of deaths from COVID-19 in New York state were men. Meanwhile, as of April 6, 82% of patients ...
MAY 16, 2020
MAY 16, 2020
Stem Cell Method (Parkinson's) Could Avoid Transplant Rejection
Researchers at McLean Hospital and Massachusetts General Hospital (MGH) have tested a stem cell treatment method that av ...
Loading Comments...